In recent trading session, VYNE Therapeutics Inc (NASDAQ:VYNE) saw 0.9 million shares changing hands at last check today with its beta currently measuring 1.68. Company’s recent per share price level of $1.36 trading at -$0.52 or -27.64% at last check today assigns it a market valuation of $20.69M. That most recent trading price of VYNE’s stock is at a discount of -216.18% from its 52-week high price of $4.30 and is indicating a discount of -5.88% from its 52-week low price of $1.44. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.11 million shares which gives us an average trading volume of 127.57K if we extend that period to 3-months.
For VYNE Therapeutics Inc (VYNE), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0 in the current quarter.
VYNE Therapeutics Inc (NASDAQ:VYNE) trade information
Upright in the red during last session for losing -27.64%, in the last five days VYNE remained trading in the red while hitting it’s week-highest on Thursday, 04/24/25 when the stock touched $1.36 price level, adding 31.77% to its value on the day. VYNE Therapeutics Inc’s shares saw a change of -59.39% in year-to-date performance and have moved -26.47% in past 5-day. VYNE Therapeutics Inc (NASDAQ:VYNE) showed a performance of -20.45% in past 30-days. Number of shares sold short was 0.14 million shares which calculate 0.75 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 5.75 to the stock, which implies a rise of 76.35% to its recent value today. Analysts have been projecting 5.75 as a low price target for the stock while placing it at a high target of 5.75. It follows that stock’s current price would drop -322.79% in reaching the projected high whereas dropping to the targeted low would mean a loss of -322.79% for stock’s current value.
VYNE Therapeutics Inc (VYNE) estimates and forecasts
This year revenue growth is estimated to fall -60.08% from the last financial year’s standing.
2 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 50k for the same. And 2 analysts are in estimates of company making revenue of 50k in the next quarter. Company posted 98k and 198k of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 65.87% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -26.60% while estimates for its earnings growth in next 5 years are of 4.50%.
VYNE Therapeutics Inc (NASDAQ:VYNE)’s Major holders
Insiders are in possession of 9.07% of company’s total shares while institution are holding 51.00 percent of that, with stock having share float percentage of 56.09%. Investors also watch the number of corporate investors in a company very closely, which is 51.00% institutions for VYNE Therapeutics Inc that are currently holding shares of the company. STALEY CAPITAL ADVISERS INC is the top institutional holder at VYNE for having 36472.0 shares of worth $71850.0. And as of 2024-06-30, it was holding 0.0857 of the company’s outstanding shares.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 373.32 shares of worth $0.52 million or 2.45% of the total outstanding shares. The later fund manager was in possession of 100.81 shares on Dec 31, 2024 , making its stake of worth around $0.14 million in the company or a holder of 0.66% of company’s stock.
